Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: Analysis using data from the cardiac insufficiency bisoprolol study II trial

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: WFRF:(Ekman Mattias) > (2001-2004) > Cost effectiveness ...

Details
MARC

Ekman, MattiasStockholm School of Economics,Handelshögskolan i Stockholm (author)

Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden : Analysis using data from the cardiac insufficiency bisoprolol study II trial

Article/chapterEnglish2001

Publisher, publication year, extent ...

Springer,2001

Numbers

LIBRIS-ID:oai:hhs.se:1155063450006056
https://research.hhs.se/esploro/outputs/journalArticle/Cost-effectiveness-of-bisoprolol-in-the/991001480687906056URI
https://doi.org/10.2165/00019053-200119090-00002DOI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:art swepub-publicationtype
Subject category:vet swepub-contenttype

Notes

Included in the thesis: 1. Studies in health economics: modelling and data analysis of costs and survival
Objective: To investigate the cost effectiveness of adding the P-blocker bisoprolol to standard treatment in patients with congestive heart failure (CHF). Design and setting: A cost-effectiveness study was based on the Cardiac Insufficiency Bisoprolol Study II (CIBIS-II), a randomised clinical trial investigating the efficacy of adding bisoprolol to standard therapy of CHF. The cost-effectiveness analysis was carried out from a societal perspective, Methods: Health effects were measured in terms of years of life gained. On the cost side, treatment costs for pharmaceuticals and hospitalisations were included. Data on healthcare resource consumption from CIBIS-II were used and were combined with average Swedish retail prices for medicines, and average costs for hospitalisations based on hospital admissions, in the base case. The costs of added years of life, i.e. consumption net of production during life-years gained were also included. Results: If costs of added years of life were not included, then bisoprolol therapy increased life expectancy at an incremental cost of Swedish kronor (SEK) 13 094 (1999 values) per year of life gained. If costs of added years of life were included, then the incremental cost-effectiveness ratio of bisoprolol therapy was SEK168 858 per year of life gained. Conclusions: For patients with CHF with the characteristics of those in CIBIS-II, the cost effectiveness of bisoprolol therapy compares favourably with that of other cardiovascular therapies.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

Zethraeus, NiklasStockholm School of Economics,Handelshögskolan i Stockholm (author)
Jönsson, BengtStockholm School of Economics,Handelshögskolan i Stockholm(Swepub:hhs)211@hhs.se (author)
Handelshögskolan i StockholmStockholm School of Economics (creator_code:org_t)

Related titles

In:PharmacoEconomics: Springer19:9, s. 901-9161179-20271170-7690

Internet link

Find in a library

PharmacoEconomics (Search for host publication in LIBRIS)

To the university's database

Find more in SwePub

By the author/editor: Ekman, Mattias; Zethraeus, Nikla ...; Jönsson, Bengt

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Cardiac and Card ...

Articles in the publication: PharmacoEconomic ...

By the university: Stockholm School of Economics

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se